A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis
A study for patients with lupus nephritis using the study drug Obinutuzumab.
Sponsor: Hoffmann-La Roche
Enrolling: Male and Female Patients
Study Length: 728 Days
Clinic Visits: 12
IRB Number: AAAP9450
U.S. Govt. ID: NCT02550652
Contact: Anca Askanase MD MPH: 212-305-0856 / ada20@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety and effectiveness of the study drug Obinutuzumab and to find out what effects, good or bad, it may have as an additional therapy in treating your lupus nephritis symptoms.
This study is closed
Investigator
Anca Askanase, MD, MPH
Do You Qualify?
Have you been diagnosed with lupus? Yes No
Have you been diagnosied with lupus nephritis? Yes No
Should you qualify for this study, would you agree to remain abstinent or use two adequate methods of contraception? Yes No
Are you pregnant or lactating? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Anca Askanase MD MPH
ada20@cumc.columbia.edu
212-305-0856
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE